Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 121278
Gene Symbol: TPH2
TPH2
0.300 Biomarker disease CTD_human
Entrez Id: 1453
Gene Symbol: CSNK1D
CSNK1D
0.200 Biomarker disease MGD
Entrez Id: 7069
Gene Symbol: THRSP
THRSP
0.200 Biomarker disease MGD
Entrez Id: 119
Gene Symbol: ADD2
ADD2
0.040 GeneticVariation disease BEFREE To determine the frequency of various behavioral manifestations, we have compared 47 random normal controls to 246 patients with TS, 17 with attention-deficit disorder (ADD), and 15 with ADD secondary to a TS gene (ADD 2(0) TS). 2890294 1987
Entrez Id: 119
Gene Symbol: ADD2
ADD2
0.040 Biomarker disease BEFREE Most of these behaviors also occurred significantly more often in individuals with ADD or in individuals with ADD secondary to TS (ADD 2(0) TS). 3479015 1987
Entrez Id: 119
Gene Symbol: ADD2
ADD2
0.040 Biomarker disease BEFREE None of the pure ADD patients had a score greater than 6, whereas 20% of the ADD-secondary-to-TS (ADD 2(0) TS) patients had scores greater than or equal to 9. 3479016 1987
Entrez Id: 119
Gene Symbol: ADD2
ADD2
0.040 Biomarker disease BEFREE Developmental milestones, problems with bladder and bowel control, sleep disturbances, allergies, and handedness were compared in 247 consecutive Tourette syndrome (TS) patients, 17 patients with attention-deficit disorder (ADD), 15 patients with ADD secondary to TS (ADD 2(0) TS), and 47 random controls. 3479017 1987
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 GeneticVariation disease BEFREE Association of attention-deficit disorder and the dopamine transporter gene. 7717410 1995
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 Biomarker disease MGD Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. 8628395 1996
Entrez Id: 8851
Gene Symbol: CDK5R1
CDK5R1
0.200 Biomarker disease MGD Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. 9010203 1997
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 Biomarker disease MGD Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. 9247269 1997
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 Biomarker disease MGD Profound neuronal plasticity in response to inactivation of the dopamine transporter. 9520487 1998
Entrez Id: 6869
Gene Symbol: TACR1
TACR1
0.500 Biomarker disease MGD Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. 9748515 1998
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 Biomarker disease MGD Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. 9888856 1999
Entrez Id: 1312
Gene Symbol: COMT
COMT
0.300 Biomarker disease CTD_human Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. 10490706 1999
Entrez Id: 140683
Gene Symbol: BPIFA2
BPIFA2
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 5723
Gene Symbol: PSPH
PSPH
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 5623
Gene Symbol: PSPN
PSPN
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 5967
Gene Symbol: REG1A
REG1A
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 4477
Gene Symbol: MSMB
MSMB
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 10247
Gene Symbol: RIDA
RIDA
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 6814
Gene Symbol: STXBP3
STXBP3
0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 Biomarker disease MGD Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. 10564358 1999
Entrez Id: 3558
Gene Symbol: IL2
IL2
0.010 Biomarker disease BEFREE While interleukin 2 (IL-2) is capable of inducing a marked expansion of the CD4 T-lymphocyte pool, limited data exist on whether IL-2 treatment can add significantly to the immunologic and virologic effects of potent antiretroviral therapy (ART). 10889591 2000
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.540 Biomarker disease MGD Hyperactivity and impaired response habituation in hyperdopaminergic mice. 11172062 2001